- Trials with a EudraCT protocol (263)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
263 result(s) found for: Experimental methods.
Displaying page 1 of 14.
EudraCT Number: 2007-004660-47 | Sponsor Protocol Number: BCX1812-203 | Start Date*: 2007-11-20 |
Sponsor Name:BioCryst Pharmaceuticals Inc | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Virologic Activity, Safety, and Pharmacodynamics of Intravenous Peramivir for the Treatment of Experimental Influenza | ||
Medical condition: Treatment of experimental influenza | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001826-99 | Sponsor Protocol Number: DANISH | Start Date*: 2005-10-19 |
Sponsor Name:Hvidovre Hospital, Dept. of Rheumatology | ||
Full Title: DANISH – a DANish multicenter study of new Imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic outcome in Spondyloarthritis patients r... | ||
Medical condition: Spondyloarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000805-26 | Sponsor Protocol Number: PSYKFORSK_MAT-MDD | Start Date*: 2021-11-19 |
Sponsor Name:Østfold Hospital Trust | ||
Full Title: An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004542-15 | Sponsor Protocol Number: SGN22E-003 | Start Date*: 2020-08-03 | |||||||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||||||||||||
Full Title: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally a... | |||||||||||||||||||||||
Medical condition: Urothelial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000810-12 | Sponsor Protocol Number: CO41101 | Start Date*: 2019-12-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META... | ||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer (TNBC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000788-95 | Sponsor Protocol Number: NSCLC1_INT | Start Date*: 2018-05-04 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
Full Title: Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-mutated lung adenocarcinoma: the FAME trial | ||||||||||||||||||
Medical condition: Patients with LKB1-mutated advanced lung adenocarcinomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003093-13 | Sponsor Protocol Number: BREAKFAST | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in the preoperative setting: the BREAKFAST trial | |||||||||||||
Medical condition: Targeting triple negative BREAst cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003736-22 | Sponsor Protocol Number: M17-142 | Start Date*: 2020-07-08 |
Sponsor Name:AbbVie Inc. | ||
Full Title: Bioavailability and Food Effect of Experimental Glecaprevir + Pibrentasvir Pediatric Formulation in Healthy Adult Subjects | ||
Medical condition: Hepatitis C virus (HCV) infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-001718-13 | Sponsor Protocol Number: MP18 | Start Date*: 2019-10-18 |
Sponsor Name:MAPS Europe B.V. | ||
Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis... | ||
Medical condition: post-traumatic stress disorder (PTSD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-000317-22 | Sponsor Protocol Number: BRE-ASA01 | Start Date*: 2017-04-13 |
Sponsor Name:Linköping University | ||
Full Title: A pilot study of low dose acetylsalicylic acid (ASA) for reduction of breast density and inflammation | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002662-12 | Sponsor Protocol Number: GINECO-EN203b | Start Date*: 2020-01-16 | ||||||||||||||||||||||||||
Sponsor Name:ARCAGY-GINECO | ||||||||||||||||||||||||||||
Full Title: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or rec... | ||||||||||||||||||||||||||||
Medical condition: metastatic or recurrent endometrial or ovarian carcinosarcoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000468-27 | Sponsor Protocol Number: BVX-010 | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:BiondVax Pharmaceuticals Ltd. | |||||||||||||
Full Title: A pivotal, multicentre, randomized, modified double-blind, placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine administered intramuscularly tw... | |||||||||||||
Medical condition: Flu vaccination | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) LV (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002715-28 | Sponsor Protocol Number: NV27779 | Start Date*: 2011-12-09 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPRE... | |||||||||||||
Medical condition: Chronic Hepatitis C (CHC), Genotype 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003211-22 | Sponsor Protocol Number: CLL12 | Start Date*: 2014-03-31 |
Sponsor Name:University of Cologne | ||
Full Title: A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients... | ||
Medical condition: Patients with Chronic Lymphocytic Leukemia Binet A stage. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005428-41 | Sponsor Protocol Number: 02044190615-01 | Start Date*: 2014-12-01 | ||||||||||||||||
Sponsor Name:Department of experimental and clincial medicine "F. Magrassi" | ||||||||||||||||||
Full Title: Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer | ||||||||||||||||||
Medical condition: The present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirim... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001641-89 | Sponsor Protocol Number: PM1183-C-003-14 | Start Date*: 2016-06-28 | |||||||||||
Sponsor Name:Pharma Mar S.A. | |||||||||||||
Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients w... | |||||||||||||
Medical condition: Small-Cell Lung Cancer (SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed) PT (Completed) CZ (Completed) NL (Completed) BG (Completed) GB (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005786-14 | Sponsor Protocol Number: 7830 | Start Date*: 2021-10-13 |
Sponsor Name:Hôpitaux Universitaires de Strasbourg B.1.2 | ||
Full Title: A randomized and controlled phase II national protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a wild type BRAF gene newly diagnosed comparing a daily oral MEK i... | ||
Medical condition: Histologically proven grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002003-37 | Sponsor Protocol Number: CHUBX2022/03 | Start Date*: 2023-03-22 | |||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Bordeaux | |||||||||||||
Full Title: Efficacy and tolerance of the association of ANIFROLUMAB (300mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind prospective,... | |||||||||||||
Medical condition: non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005549-30 | Sponsor Protocol Number: ESR-15-11421 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University | |||||||||||||
Full Title: A single-dose cross-over study to assess direct and indirect effects of dapagliflozin on pancreatic alpha and beta cells in patients with type 2 diabetes | |||||||||||||
Medical condition: Effects on pancreatic alpha and beta cells in patients with type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000790-38 | Sponsor Protocol Number: CRSV 604A 2203 | Start Date*: 2008-07-01 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus | ||
Medical condition: infection with respiratory syncytial virus | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
